BioBay, the industrialisation hub where contract pharmaceutical services provider CMab Biopharm is located, is among its investors.
BioBay, an industrialisation services provider that forms part of Suzhou Industrial Park, has co-led a $38m series A round for China-based contract pharmaceutical services startup CMab Biopharm today.
Private equity firm C-Bridge Capital co-led the round with BioBay, investing together with I-Bridge Capital and Qianhai Fund of Funds.
CMab, which is based in BioBay, provides preclinical and early-stage clinical development and manufacturing services such as cell line development for biopharmaceutical researchers.
The company’s work ensures their client’s drug research and manufcaturing…
